Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Stone, John H., Merkel, Peter A., Spiera, Robert, Seo, Philip, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Turkiewicz, Anthony, Tchao, Nadia K., Webber, Lisa, Ding, Linna, Sejismundo, Lourdes P., Mieras, Kathleen, Weitzenkamp, David, Ikle, David, Seyfert-Margolis, Vicki, Mueller, Mark, Brunetta, Paul, Allen, Nancy B., Fervenza, Fernando C., Geetha, Duvuru, Keogh, Karina A., Kissin, Eugene Y., Monach, Paul A., Peikert, Tobias, Stegeman, Coen, Ytterberg, Steven R., Specks, Ulrich
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3137658/
https://ncbi.nlm.nih.gov/pubmed/20647199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0909905
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items